Global utilization of low-dose corticosteroids in severe sepsis and septic shock: a report from the PROGRESS registry.
BACKGROUND
The benefits and use of low-dose corticosteroids (LDCs) in severe sepsis and septic shock remain controversial. Surviving sepsis campaign guidelines suggest LDC use for septic shock patients poorly responsive to fluid resuscitation and vasopressor therapy. Their use is suspected to be wide-spread, but paucity of data regarding global practice exists. The purpose of this study was to compare baseline characteristics and clinical outcomes of patients treated or not treated with LDC from the international PROGRESS (PROmoting Global Research Excellence in Severe Sepsis) cohort study of severe sepsis.


METHODS
Patients enrolled in the PROGRESS registry were evaluated for use of vasopressor and LDC (equivalent or lesser potency to hydrocortisone 50 mg six-hourly plus 50 microg 9-alpha-fludrocortisone) for treatment of severe sepsis at any time in intensive care units (ICUs). Baseline characteristics and hospital mortality were analyzed, and logistic regression techniques used to develop propensity score and outcome models adjusted for baseline imbalances between groups.


RESULTS
A total of 8,968 patients with severe sepsis and sufficient data for analysis were studied. A total of 79.8% (7,160/8,968) of patients received vasopressors, and 34.0% (3,051/8,968) of patients received LDC. Regional use of LDC was highest in Europe (51.1%) and lowest in Asia (21.6%). Country use was highest in Brazil (62.9%) and lowest in Malaysia (9.0%). A total of 14.2% of patients on LDC were not receiving any vasopressor therapy. LDC patients were older, had more co-morbidities and higher disease severity scores. Patients receiving LDC spent longer in ICU than patients who did not (median of 12 versus 8 days; P <0.001). Overall hospital mortality rates were greater in the LDC than in the non-LDC group (58.0% versus 43.0%; P <0.001). After adjusting for baseline imbalances, in all mortality models (with vasopressor use), a consistent association remained between LDC and hospital mortality (odds ratios varying from 1.30 to 1.47).


CONCLUSIONS
Widespread use of LDC for the treatment of severe sepsis with significant regional and country variation exists. In this study, 14.2% of patients received LDC despite the absence of evidence of shock. Hospital mortality was higher in the LDC group and remained higher after adjustment for key determinates of mortality.
Division of Asthma, King's College London, Guy's, Campus, Great Maze Pond, London SE1 9RT, UK. richard.beale@gstt.nhs.uk
Richard
R
Beale
Jonathan M
JM
Janes
Frank M
FM
Brunkhorst
Geoffrey
G
Dobb
Mitchell M
MM
Levy
Greg S
GS
Martin
Graham
G
Ramsay
Eliezer
E
Silva
Charles L
CL
Sprung
Benoit
B
Vallet
Jean-Louis
JL
Vincent
Timothy M
TM
Costigan
Amy G
AG
Leishman
Mark D
MD
Williams
Konrad
K
Reinhart
D000305:Adrenal Cortex Hormones / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007362:Intensive Care Units; D008875:Middle Aged; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data; D057216:Propensity Score; D011446:Prospective Studies; D012042:Registries; D012772:Shock, Septic / Q000188:drug therapy* / Q000401:mortality; D016896:Treatment Outcome; D014662:Vasoconstrictor Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
D000305:Adrenal Cortex Hormones; D014662:Vasoconstrictor Agents